Luciano Costa, Professor of Medicine at UAB Medicine, shared on X:
“ASH26 Top 10 MMSM abstracts in no particular order
- MonumenTAL6 – new benchmark for Len and anti-CD38 exposed RRMM
- Tunlu-cel, dual targeting does it again. small N, but best PFS reported in triple-class exposed RRMM with any CAR-T cell.
- MagnetisMM-5. Elra in early relapse RRMM. We would be all wondering what would be the result with an anti-CD38 mAb
- ExcaliBER-RRMM, the PFS we all wanted to see.
- Moderna’s mRNA-2808 Early promising result on a brand new multiplex platform. The future is multi-targeted.
- ABBV-2001 A GPRC5D-free trispecific, continues to deliver.
- Anitocel, finally the PFS, a bit underwhelming.
- AnitoFIRST consolidation after induction.
- MajesTEC-5 Ramantamig in first line. Impressive
- COMMANDER Finish the job and get rid of MRD after ASCT.”
About ASH 2026
The American Society of Hematology (ASH) Annual Meeting and Exposition is one of the world’s leading events in hematology, bringing together physicians, researchers, and healthcare professionals to discuss the latest advances in blood cancer research and the treatment of blood disorders.
ASH 2026 will highlight new clinical trial results, emerging therapies, and scientific developments across hematology, with particular attention to multiple myeloma, leukemia, lymphoma, and other blood-related diseases.
The 68th ASH Annual Meeting will take place December 12-15, 2026, in New Orleans, Louisiana, with a virtual attendance option. It is expected to bring together more than 30,000 participants and feature thousands of scientific abstracts.
You may also be interested in:
- Mehak Trehan: 10 Pivotal Myeloma Abstracts to Watch at ASH 2026
- Talha Badar’s ASH 2026 Watchlist: 11 Key AML Studies